Radiopharm Theranostics (RAD) investor relations material

Company overview and business model

• Focuses on developing and commercializing radiopharmaceutical platforms for precision oncology, targeting both therapeutic and diagnostic applications in solid tumors with high mortality rates.

• Pipeline includes five licensed platform technologies and a joint venture with MD Anderson to develop novel radiopharmaceutical products.

• Engages in partnerships with nuclear medicine suppliers and leading academic institutions to secure isotopes and expand clinical assets.

• Pursues global regulatory approvals, aiming for FDA approval and subsequent expansion into the EU, UK, China, Japan, Australia, and Canada.

• Maintains a global intellectual property strategy, seeking patent protection in key markets.

Financial performance and metrics

• Raised approximately US $3.3 million in July 2026 through a private placement of 1,345,728 ADSs (representing 403,718,400 ordinary shares).

• As of December 31, 2025, had cash and cash equivalents of A$34.5 million (actual) and A$45.8 million (as adjusted for recent offerings).

• Equity as of December 31, 2025, was A$49.9 million (actual) and A$61.2 million (as adjusted).

• No current product revenue and a history of operating losses; additional financing will be required for ongoing R&D and commercialization.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of ADSs by selling shareholders, except up to US $5.1 million upon exercise of warrants.

• Proceeds from warrant exercises will support ongoing operations and development activities.